Boston Scientific Corporation · BSX · Next earnings

Boston Scientific Corporation reports Wednesday, Oct 28, 2026

BSX reports before market open with consensus EPS at $0.79 and revenue at $5.19B. Last quarter: Boston Scientific Beats Q1 but Lowers Full-Year Guidance on EP and WATCHMAN Headwinds

Reports Before market open38 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $0.79 Calendar consensus
Consensus revenue $5.19B Calendar consensus
Report date Oct 28, 2026 Wednesday, date estimated
Session Before market open 38 days away

Where BSX left off: FY2026 Q1

Full report

Boston Scientific Beats Q1 but Lowers Full-Year Guidance on EP and WATCHMAN Headwinds

EPS surprise +1.5% Reported $0.80 vs $0.79
Revenue surprise +0.6% Reported $5.20B vs $5.17B
Stock move +9.0% Event window
Subsequent drift -12.6% Up to 20 sessions

Full-year organic revenue growth guidance was lowered to 6.5%-8% and adjusted EPS guidance was reduced to $3.34-$3.41. The guidance cut reflects three specific headwinds: (1) unexpected deceleration in electrophysiology, partly tied to the accelerated discontinuation of the POLARx cryoablation system following safety events; (2) WATCHMAN volume trends falling below expectations; and (3) urology weakness with only 1% organic growth, prompting new product launches and commercial hiring.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Unanticipated headwinds in EP, WATCHMAN, and urology leading to lower guidance.
  • Intensifying competition in pulsed field ablation from Medtronic, J&J, and Abbott.
  • Supply-chain disruptions affecting endoscopy and other product lines.
  • Regulatory timing risk for new indications and product launches.
  • Integration risk and valuation uncertainty surrounding the Penumbra acquisition.

Questions analysts left open

  • Reasons for lowering full-year guidance and whether headwinds are temporary or structural.
  • EP market share assumptions and U.S. EP outlook amid PFA competition.
  • WATCHMAN volume trends and stand-alone vs concomitant growth trajectory.
  • Urology sales weakness and whether commercial turnover and new products can reverse the trend.
  • Funding and timing of the $2B share buyback amid the Penumbra deal.

Ask FN2 about BSX next report

Transcript, numbers and history already loaded
What should I watch for in BSX's next earnings report?How did BSX guide last quarter, and is consensus above or below that?Give me the bull and bear case going into BSX earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the BSX recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent BSX quarters

All BSX earnings
+9.0%FY2026 Q1

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q1

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.